Andaman Medical Phils.Corp.
Business Opportunity Assessment Report

Company Snapshot

Andaman Medical Philippines Corporation is a Philippine-registered entity operating as the local arm of Andaman Medical—a Singapore-headquartered regulatory affairs and market access consultancy specializing in medical devices and IVDs across Southeast Asia. It functions primarily as an Authorized Representative, import license holder, and regulatory facilitator—not a manufacturer or end-product seller—enabling foreign medical device firms to comply with Philippine FDA requirements and clear customs efficiently. Its operational structure reflects a service-led, license-based model tightly integrated with regional offices in Indonesia, Thailand, and Singapore. A notable shift occurred in 2024–2026: Manila port usage dropped from dominant to inactive (‘lost’), while trade activity surged with Australia and Sweden—indicating strategic realignment toward upstream regulatory support rather than domestic distribution.

Company Attributes

Trade Trend Analysis

Data interpretation reveals extreme volatility in monthly transaction volume—ranging from 21 units (Jul 2024) to over 2 million units (Nov–Dec 2025)—with no consistent seasonal pattern. This reflects event-driven, project-based engagement (e.g., batch registrations, license renewals, or large-scale import clearances), not recurring product sales. The sharp drop in Jan 2026 (13.7K units) followed by recovery in Feb (1.01M) suggests dependency on client-specific regulatory timelines rather than organic demand cycles. Transaction frequency remains high (43–220/month), confirming sustained service delivery capacity.

The structural volatility signals operational reliance on discrete, high-stakes regulatory milestones—not steady-state commerce.

Trade Partner Analysis

Data interpretation shows strong concentration: ResMed Asia Pacific Ltd. (Australia) and Vitrolife Sweden AB alone account for 67.7% of total transactions—indicating deep, long-term partnerships with global medtech leaders requiring multi-market regulatory orchestration. Top partners are all established OEMs/brand owners (not distributors), aligning with Andaman’s role as their independent Authorized Representative. New entrants (e.g., Wego Healthcare China, Erbe Germany) reflect geographic expansion into APAC supply chain hubs and EU-aligned markets—yet remain marginal (<1% each). No Filipino suppliers appear in top 20, confirming its non-manufacturing, service-only position.

This partner profile confirms Andaman’s function as a trusted regulatory interface—not a commercial buyer or distributor.

HS Code Analysis

Data interpretation highlights functional categorization over product classification: HS codes cluster around diagnostic instrumentation (90330000000 — electrical apparatus for measuring or checking electrical quantities), reagents (38210010000 — diagnostic reagents), therapeutic equipment (90192090000 — other electro-therapeutic apparatus), and ancillary components (e.g., 85444949000 — insulated electric conductors). This mirrors Andaman’s service scope—facilitating imports of regulated medical hardware, consumables, and calibration tools required for registration and clinical validation. Notably, no HS codes correspond to finished consumer devices (e.g., blood pressure monitors), reinforcing its non-retail, non-OEM identity.

These HS patterns confirm alignment with regulatory enablement—not product distribution or manufacturing.

Trade Region Analysis

Data interpretation shows decisive regional focus: Australia (40.0%), Sweden (24.4%), and Malaysia (16.3%) collectively represent 80.7% of all transactions—reflecting Andaman’s core mandate in ASEAN+EU/AU regulatory corridors. The Philippines itself appears only as a ‘lost’ trading partner (11.8%, last transacted Nov 2024), confirming the subsidiary’s role as a local legal vehicle, not a domestic buyer. Recent additions (Japan, Germany, China) signal deliberate expansion into high-compliance markets where Andaman’s independent AR model offers competitive differentiation versus local distributor-controlled licensing.

This geographic skew underscores specialization in cross-border regulatory navigation—not local market penetration.

Export Port Analysis

Data interpretation reveals near-total historical reliance on Manila port (96.7% of transactions), now fully inactive since Nov 2024—confirming cessation of physical import operations by the Philippine entity. Cebu port (3.3%) also inactive since Oct 2024. This port abandonment coincides with documented shift toward digital regulatory submissions and remote license management—meaning Andaman Philippines now operates purely as a legal and compliance entity, with zero physical logistics footprint. No active ports remain in current data, validating its evolution into a ‘virtual regulatory office’.

The complete port deactivation confirms transition from import facilitation to pure regulatory representation.

Contact Information

• Official Website: https://www.andamanmed.com/
• LinkedIn: https://www.linkedin.com/company/andaman-medical
• Facebook: https://www.facebook.com/andamanmedical
• Email: info@andamanmed.com (publicly listed on contact page)
• Phone: +65 6223 0108 (Singapore HQ; Philippine office uses shared regional contact)
• Head Office Address: 10 Tampines Junction, Level 11, Singapore 529536
• Philippine Registered Address: Las Pinas City, Philippines (exact street address not publicly disclosed)

Company Trade Summary

• Andaman Medical Philippines Corporation is a legally registered but operationally virtual entity—its trade data reflects regulatory service execution, not physical commerce.
• Core value lies in enabling foreign medtech firms to meet Philippine FDA requirements via Authorized Representative designation, import licensing, and post-market surveillance—not product resale or manufacturing.
• HS code profile (9033, 3821, 9019) validates its role in clearing diagnostic instruments, reagents, and therapeutic devices—not generic medical supplies.
• Complete port deactivation (Manila/Cebu) and absence of domestic suppliers confirm full decoupling from physical import/distribution.
• Dominant partnerships with ResMed and Vitrolife demonstrate trust in high-stakes, multi-jurisdictional regulatory execution—making it a low-risk, high-credibility channel for market entry.